A randomized study conducted by the US National Institute of Allergy and Infectious Diseases at 10 medical centers tested the drug Xolair (used to treat asthma) in 177 children aged 1-18 and 3 adults allergic to peanuts and at least 1 other food such as milk or eggs.
Participants took Xolair for 16 to 20 weeks, with the dose based on weight and the amount of allergy-related antibodies in their blood.
The results after treatment were that 67% of children did not develop allergic symptoms when given small amounts of peanut protein. The corresponding rate among the other 59 children given a placebo was only 7%. About 44% of those given the drug could consume 25 soybeans without allergic reactions. 41% of those allergic to cashews could consume 1,000 mg of cashew protein, while the corresponding rate in the placebo group was 3%. The difference in the milk allergy group was 66%-10%, and in the egg allergy group was 68%-0%.
Most of the 38 children who participated in the trial for another 24 weeks showed stable results and increasingly higher tolerance levels. This February, the US Food and Drug Administration (FDA) approved the use of Xolair for children 1 year and older to treat food allergies.
LAM DIEN
Source
Comment (0)